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Scientists in the Health and Environmental Review Division (HERD), Office of Toxic Substances
of the U.S. Environmental Protection Agency, are examining the feasibility of expanding efforts in
short-term carcinogen testing. Three areas for consideration have been defined. These are (1) short-
term in vitro tests; (2) short-term in vivo tests; and (3) tumor markers.
HERD's current efforts in short-term in vitro testing are exemplified by the Gene-Tox program.
Through a comprehensive system of committees and reviews, the published literature on eukaryotic
and prokaryotic in vitro and in vivo test systems are being examined and analyzed. The suitability
of utilizing the various systems in a test battery to identify potential chemical mutagens and car-
cinogens will be ascertained.
A review of the literature on short-term in vivo tests (limited bioassays) and tumor markers is cur-
rently being conducted. Correlations will be made between results obtained from these tests and
epidemiological information and long-term animal bioassays. The attributes and deficiencies of
each test or marker will be examined. Further testing, development, or validation needs will be
outlined. The aim of this review is to attempt to expand the prechronic test battery for carcinoge-
nicity in order to provide sufficient information for regulatory decision-making.
Section 5 of the Toxic Substances Control Act
(TSCA) requires industry to notify the Environmen-
tal Protection Agency (EPA) of its intent to initiate
manufacturing or processing of a new chemical, or if
an existing chemical will be used in a significantly
new way. Section 4 of TSCA gives EPA the authori-
ty to require industry to conduct testing when
there is evidence that a chemical may present an
unreasonable risk to health or the environment, and
when there is substantial exposure of humans or
the environment to the chemical. Both of these sec-
tions of TSCA, therefore, provide for the initiation
of detailed reviews on chemicals and their analogs.
The process begins with a thorough evaluation of
the published literature and any data supplied by
industry. Results from studies being conducted by
other government agencies and the National Toxicol-
ogy Program also are evaluated by EPA scientists.
Following this comprehensive review, it may be
concluded that sufficient information about the po-
tential carcinogenicity of the chemical is already
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available in order to make a hazard assessment. On
the other hand, it may be concluded that additional
testing may be required. If short-term tests are rec-
ommended, results from these tests may indicate
that no further testing is needed, or that the chemi-
cal might be a potential carcinogen and that a defin-
itive long-term animal bioassay should be con-
ducted.
While the long-term animal bioassay is the best
available method for the detection of animal carcino-
gens, it nevertheless is very time-consuming, expen-
sive, and often provides ambiguous results. Clearly,
to circumvent these problems, more research is
needed in short-term carcinogen testing.
Three distinct areas for research have been iden-
tified by scientists at the EPA. These are (1) short-
term in vitro tests, which are exemplified by the
Gene-Tox Program; (2) short-term in vivo tests or
limited bioassays; and (3) tumor markers. At pres-
ent, only tests which identify complete carcinogens
are being examined, although the applicability of
these tests to the identification of tumor promoters
may also be investigated. None of the tests in any of
these research areas provide direct evidence that a
chemical is a carcinogen. However, if used in a pre-MILMAN, HURLEYAND A ULETTA
chronic carcinogenicity screen, results from such
tests may yield suggestive, or supportive, evidence
for the potential carcinogenicity of a compound, and
may help in deciding whether additional long-term
animal testing is necessary.
The first area of research that I would like to dis-
cuss is the area of short-term in vitro tests. Most of
you are already familiar with the Gene-Tox Pro-
gram, whose overall objective is to evaluate syste-
matically the current utility of selected mutagenic-
ity and related assay systems based on the avail-
able literature. Those assays which have been se-
lected for comprehensive evaluation are based on
gene mutations, chromosomal effects, primary DNA
damage, or oncogenic transformation. The evalua-
tions are being conducted by scientists representing
academia, industry, and government working
through a series of committees to examine the feasi-
bility of using these methods in a prechronic
testing battery for carcinogenicity.
The next area I would like to discuss is the short-
term in vivo test. A comprehensive examination of
the literature on limited bioassays is being con-
ducted in order to identify potential short-term in
vivo tests for carcinogens. This review will include
an analysis of the data on each selected bioassay for
use as a confirmatory test in the carcinogenicity
screen. Data base and other validation needs will be
identified including false positives and false nega-
tives. Correlations will be made between results
obtained with the in vivo tests under consideration
and epidemiologic information and long-term animal
bioassays.
The initial review identified over 20 different
short-term in vivo bioassays for consideration. From
these, five were selected for in-depth analysis.
These include (1) the Sencar mouse-skin tumorigen-
esis with and without promotion; (2) pulmonary tu-
mor induction in strain A mice; (3) pulmonary tumor
induction in newborn mice; (4) mammary tumor in-
duction in female Sprague-Dawley rats; and (5) in-
duction of iron-resistant liver foci in rats.
The in-depth analysis of these various short-term
in vivo tests will be completed within approximate-
ly three months. Following this analysis of the liter-
ature, laboratory testing of selected bioassays will
begin to fill in the data base gaps and to complete
the validation of the selected bioassays as predic-
tive tools for carcinogenicity.
The next area of research that I would like to dis-
cuss is our efforts on the potential use of tumor
markers for carcinogen screening. Ideally, it would
be quite advantageous if a marker could be found in
the blood which is specific for malignant neoplasms.
Such a marker could have several potential uses.
For example, it could be used to detect cancers in
humans when the tumors are still small and there-
fore can be most readily treated. It could also be
used to follow patients with cancer who are on
chemotherapy. That is, as the tumor regresses, the
marker may disappear, signifying that the chemo-
therapy is working. In fact, several identified
markers are being used today in just this way. A
third possible use of tumor markers is to monitor
workers exposed to potential carcinogens. Should
these workers develop cancer, these markers will
be elevated in the blood and the tumor may be de-
tected at an early stage of development when,
again, treatment is most effective. Finally, a fourth
potential use of tumor markers is the early detec-
tion of cancer in experimental animals who are ex-
posed to potential carcinogens. It is to this last use
that I would like to address the rest of my presenta-
tion.
Over 25 tumor markers have been mentioned in
the literature. Of these, a-fetoprotein and carcino-
embryonic antigen have been studied the most.
Most of what is known about these markers is
through work conducted in humans and human can-
cers. The potential applicability of using some of
these markers in carcinogen testing in rodents is
currently being investigated.
The published literature is being searched for in-
formation on cancer markers. The data on each se-
lected marker will be analyzed for use as a confir-
matory test in the prechronic carcinogenicity
screen. When possible, correlations will be made
between the ability of each marker to detect known
carcinogens or target-organ specificity. Each mark-
er will be ranked as a possible candidate for use in a
prechronic test battery.
Where animal and human data exists, this will be
specified and correlations will be made. The attri-
butes and deficiencies of each marker, such as false
positives and false negatives, chemical-class or tar-
get-organ specificity will be identified. Finally, the
markers selected for potential use in the prechronic
test battery will be further tested and validated, as
necessary.
I would like to give just one example of the po-
tential uses of these tumor markers. Serum levels
of a-fetoprotein are elevated during the administra-
tion of 2-AAF and during the growth period of a
transplanted hepatoma. On removal of the tumor,
the marker level goes down. On regrowth of the tu-
mor, the serum level of a-fetoprotein begins to rise
again. Concentrations of a-fetoprotein in the serum
also increase during injury to the liver, as with car-
bon tetrachloride, or during hepatectomy or preg-
nancy. During the testing of potential carcinogens,
some of these variables could be controlled. The fact
that the concentration of a-fetoprotein increases
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during noncarcinogenic toxic injury as well as
during the growth of neoplasms shows that this
marker only produces suggestive evidence for the
potential carcinogenicity of a compound. However,
additional research in this area can potentially lead
to more specificity among markers.
In summary, scientists at the EPA are examining
the feasibility of expanding the efforts in short-term
carcinogen testing. These efforts include short-term
in vitro tests, short-term in vivo tests, and tumor
markers. It is envisioned that ultimately, the pre-
chronic test battery for potential carcinogens may
be expanded to include not only tests based on mu-
tagenic endpoints or cell transformation assays, but
also results from short-term in vivo tests and tumor
markers. Taken together, such tests should supply
sufficient information to indicate whether additional
definitive long-term animal bioassays are required.
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